1. Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori
- Author
-
Mamoru Takenaka, Teppei Adachi, Hiroshi Kashida, Masatoshi Kudo, Ayana Okamoto, Kosuke Minaga, Masashi Kono, Naoshi Nishida, Toshiharu Sakurai, Yutaka Asakuma, Kazuki Okamoto, Tomoyuki Nagai, Shigenaga Matsui, Yoriaki Komeda, Tomohiro Watanabe, Kentaro Yamao, Mitsunari Yamada, and Ken Kamata
- Subjects
Cancer Research ,medicine.medical_specialty ,Helicobacter pylori infection ,biology ,business.industry ,First line ,macromolecular substances ,General Medicine ,Amoxicillin ,Helicobacter pylori ,biology.organism_classification ,Gastroenterology ,Esomeprazole ,03 medical and health sciences ,Metronidazole ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Internal medicine ,Clarithromycin ,medicine ,030211 gastroenterology & hepatology ,Prospective cohort study ,business ,medicine.drug - Abstract
Introduction: Clarithromycin (CAM)-based triple therapy comprising proton pump inhibitors and amoxicillin is administered as first-line eradication treatment against Helicobacter pylori infection. However, the eradication rate achieved with CAM-based triple therapy has decreased to H. pylori eradication. Methods:H. pylori-positive patients were treated with CAM-based triple therapy comprising esomeprazole and amoxicillin (EAC group) or with MNZ-based triple therapy comprising esomeprazole and amoxicillin (EAM group). Results:H. pylori eradication rates achieved in the intention-to-treat (ITT) and per protocol (PP) analyses were 70.6 and 72.7%, respectively, in the EAC group. Eradication rates obtained via ITT and PP analyses were 91.7 and 94.3%, respectively, in the EAM group. In the EAC group, eradication rates were significantly lower in patients harboring CAM-resistant strains than in those harboring CAM-sensitive strains. In contrast, eradication rates were comparable between patients harboring CAM-resistant strains and those harboring CAM-sensitive strains in the EAM group. Conclusion: MNZ-based triple therapy consisting of esomeprazole and amoxicillin is superior to CAM-based triple therapy containing esomeprazole and amoxicillin as first-line eradication treatment against H. pylori.
- Published
- 2017